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Abstract: Glioblastoma is the most common and invasive primary tumor of the central nervous
system and normally has a negative prognosis. Biodistribution in healthy animal models is an
important preliminary study aimed at investigating the efficacy of chemotherapy, as it is mainly
addressed towards residual cells after surgery in a region with an intact blood–brain barrier.
Nanoparticles have emerged as versatile vectors that can overcome the blood–brain barrier. In this
experimental work, solid lipid nanoparticles, prepared using fatty acid coacervation, have been
loaded with an active lipophilic ester of cytotoxic drug methotrexate, and functionalized with either
transferrin or insulin, two proteins whose receptors are abundantly expressed on the blood–brain
barrier. Functionalization has been achieved by grafting a maleimide moiety onto the nanoparticle’s
surface and exploiting its reactivity towards thiolated proteins. The nanoparticles have been
tested in vitro on a blood–brain barrier cellular model and in vivo for biodistribution in Wistar
rats. Drug metabolites, in particular 7-hydroxymethotrexate, have also been investigated in the
animal model. The data obtained indicate that the functionalization of the nanoparticles improved
their ability to overcome the blood–brain barrier when a PEG spacer between the proteins and
the nanoparticle’s surface was used. This is probably because this method provided improved
ligand–receptor interactions and selectivity for the target tissue.
Keywords: solid lipid nanoparticles; blood–brain barrier; methotrexate; insulin; transferrin
1. Introduction
Glioblastoma multiforme (GB), a grade IV glioma, is the most frequently occurring and invasive
primary tumor of the central nervous system (CNS) and causes approximately 4% of cancer-associated
deaths, making it one of the most fatal cancers worldwide. Median survival with present therapies is
about 14 months, and the 2-year survival rate is merely 3–5% [1].
GB pharmacological therapy is currently only adjuvant; it is used subsequent to surgery and either
subsequent to or simultaneously with radiotherapy. It is rarely applied as the first treatment option.
GB chemotherapeutic drugs are rarely effective despite the fact that the blood–tumor barrier (BTB), in
malignant brain tumors, is more permeable than the blood–brain barrier (BBB) [2]. In fact, drugs should
mainly be addressed towards the eradication of residual tumor cells after surgery or radiotherapy.
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This cell population includes cells that migrate from the tumor into healthy tissue (and which were not
destroyed by previous treatment) or that feed the tumor from, still active, distant sites. The critical zone
for the treatment of glioblastoma is the area surrounding it, named BAT (Brain Adjacent to Tumor),
including cells in the invasion phase and those coming into the tumor, which, unlike those within
the tumor, maintain an intact BBB. Since BAT is the main target of chemotherapy, the development
of chemotherapeutic formulations that can cross an intact BBB is essential [3]. Classical cytotoxic
drugs, which have high in vitro efficacy against GB, have difficulty in overcoming the BBB. The BBB
is, therefore, a major limitation to drug therapy [4]. Moreover, in addition to tight junctions, the BBB
also bears, on the luminal surface, many efflux membrane transporters, such as P-glycoprotein (Pgp)
and multidrug-related proteins (MRP) that recognize several anticancer drugs as substrates [5]. The
biodistribution of cytotoxic drugs in healthy animal models with intact BBB is, therefore, an important
preliminary study that can be used to foresee the efficacy of chemotherapy against GB.
Nanocarriers are drug transport systems that have gained a great deal of attention over recent
decades for their ability to facilitate site-specific drug delivery, including brain delivery [6]. In particular,
solid lipid nanoparticles (SLNs) have been proposed as innovative vehicles for chemotherapeutic
agents in experimental GB treatment because of their ability to enhance drug uptake by cells and to
evade the Pgp efflux system. It is well known that SLNs are subject to endocytosis by endothelial cells
and can be targeted to specific tissues [7].
In a recent work, SLNs were prepared using an innovative technology (coacervation method),
and loaded with a lipophilic ester prodrug of methotrexate (MTX)—didodecylmethotrexate
(ddMTX)—with good entrapment efficiency. ddMTX-loaded SLNs demonstrated promising
cytotoxicity against GB primary cell cultures [8]. The subsequent in vivo biodistribution studies,
performed in healthy rats and in glioma models, gave encouraging results. However, the ability
to overcome the BBB was still too poor to achieve significant results on tumor growth in glioma
models [9]. Major improvements would include an increase in the SLN plasmatic concentration,
and the implementation of a successful BBB targeting strategy. To this aim, this experimental work
improves the ddMTX-loaded SLN formulation technique by reducing the size and polydispersity
of the nanoparticles and optimizing their hydrophilic coating. Moreover, ddMTX-loaded SLNs
were functionalized with either transferrin (TRF) or insulin (INS), two proteins whose receptors are
abundantly expressed on the BBB, using maleimide-thiol chemistry. The nanoparticles were tested
in vitro on blood–brain barrier cell models and in vivo for biodistribution on Wistar rats. In vivo drug
metabolism was also investigated in the animal model.
2. Materials and Methods
2.1. Materials
Sodium behenate was from Nu-Chek Prep, Inc. (Eleisyan, MN, USA); sodium stearate, bovine
INS, TRF, dimethylsulfoxide (DMSO), dimethylformammide (DMF), MTX, stearylamine, sodium
dodecyl sulfate (SDS), potassium permanganate, hydrogen peroxide (H2O2), acetic acid, triethylamine,
dextran (Mw 60,000–90,000), tris(carboxyethyl)phosphine hydrochloride (TCEP), iminothiolane,
3-maleimidobenzoic acid N-hydroxysuccinimide ester (MBS), N-hydroxysuccinimide (NHS),
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 3-methylisoquinoline, ethanol, methanol,
acetonitrile, hydrolyzed polyvinyl alcohol of 89% 80,000–120,000 Mw (PVA120000) and 80% hydrolyzed
polyvinyl alcohol of 9000–10,000 Mw (PVA9000) were from Sigma Aldrich (Saint Louis, MO, USA);
stearic acid, tris(hydroxymethyl)aminomethane (TRIS), phosphoric acid, hydrochloric acid, sodium
acetate, ammonium chloride, potassium chloride, ammonium sulphate, potassium ferricyanide and
sodium hydroxide were from Merck (Darmstadt, Germany); ethylendiaminotetraacetic acid (EDTA),
chloroform, methanol and ethanol were from Carlo Erba (Cornaredo, Italy); diaminopoliethylenglycol
2000 Mw (diamino-PEG) was from Iris Biotech GmbH (Marktredwitz, Germany); lactic acid was from
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A.C.E.F. (Fiorenzuola, Italy); deionized water was obtained by a MilliQ system (Millipore, MO, USA).
All other chemicals were of analytical grade and used without any further purification.
Electrophoresis reagents were from Bio-Rad Laboratories (Hercules, CA, USA). When not
otherwise specified, all the other reagents were from Sigma Chemicals Co.
2.1.1. Cells
Human Cerebral Microvessel Endothelial Cells/Dilution Cloning Number 3 (hCMEC/D3 cells),
a human brain microvascular endothelial cell line that retains the properties of BBB in vitro, were
cultured as reported [10,11]. Cells were seeded at 50,000/cm2 and grown for 7 days up to confluence in
Petri dishes and Transwell devices (0.4 µm diameter pores-size, Corning Life Sciences, Chorges, France).
2.1.2. Animals
Male Wistar rats (Charles River, MA, USA), weighing 200–250 g, were housed in standard
facilities, handled and maintained according to our Institutional Animal Care and Use Committee
ethical regulations. The rats were kept under controlled environmental conditions (23 ± 1 ◦C, 50–60%
humidity, 12 h light and dark cycles, lights on at 7:00 a.m.). The rats were given ad libitum access
to food and water. The procedures conformed to the Ethics Committee of the University of Turin’s
institutional guidelines on animal welfare (DL 26/2014 implementation of directive 2010/63 UE) as
well as International Guidelines, and all efforts were done to minimize the number of animals and
their discomfort. All experiments on animal models were performed according to an experimental
protocol approved by the University Bioethical Committee and the Italian Ministry of Health (Prot. N.
135/2015, 29/09/2015).
2.2. Methods
2.2.1. ddMTX Synthesis
The lipophilic ester, ddMTX, was synthesized according to the literature [12,13]. Briefly, 100 mg
MTX and 71.5 mg cesium carbonate and 120 µL dodecyl bromide (corresponding to 125 mg; d = 1.04)
were dissolved in 6 mL DMSO and left to react under stirring for 24 h. The molar ratio between
MTX, cesium carbonate and dodecyl bromide is 1:1:2. ddMTX was precipitated from the reaction
mixture by adding 5 mL water and then extracted with 3 mL chloroform, which was repeated 5 times.
The organic phase was reduced to 6 mL under nitrogen steam, and DMSO was removed by extracting
with 5 mL sodium chloride saturated solution, which was repeated 3 times. The organic phase was then
evaporated under nitrogen steam and the residue was purified through Silica column by employing a
chloroform/methanol gradient.
The obtained product was characterized through High Performance Liquid Chromatography
(HPLC). Analyses were performed with a LC10 HPLC UV system (Shimadzu, Tokyo, Japan), linked
to a Class LC10 software (v1.4, Shimadzu, Tokyo, Japan, 1994) for data analysis. The column was a
Teknokroma Kromosil 100 Si 25 cm × 0.46 nm, the UV wavelength was set at 302 nm, the mobile phase
was dichlorometane/methanol 95/5 at 1 mL/min. 1H NMR spectra were recorded on a Jeol ECZ-R
600 (Jeol Ltd, Tokyo, Japan), at 600 and 150 MHz, respectively, using SiMe4 as the internal standard.
The following abbreviations are used to designate peak multiplicity: s = singlet, d = doublet, t = triplet,
m = multiplet, bs = broad singlet. ESI–MS spectra were recorded on a Micromass Quattro API micro
(Waters Corporation, Milford, MA, USA) mass spectrometer. Data were processed using a MassLynx
System (v4.1, Waters, 2009).
2.2.2. Lipophilic Linker N-Octadecil-3-Maleimido-Benzamide (ST-MBS) Synthesis
ST-MBS was synthesized according to a method in the literature, slightly modified [14]. Amounts
of 4.5 mg stearylamine and 5 mg MBS were dissolved in 1 mL CHCl3 and 15 µL di-triethylamine and
were kept reacting at 40 ◦C for 4 h. The chloroform phase was extracted twice with 1% NaCl and twice
Pharmaceutics 2019, 11, 65 4 of 18
with distilled water to remove water-soluble by-products. MgSO4 was added to the chloroform phase
and filtered. The mixture was dried from chloroform using a rotor-evaporator.
The reaction was assessed through Thin Layer Chromatography (TLC—acetic
acid/chloroform/methanol 1/89/10). The product was characterized through HPLC. Analyses were
performed with a YL9100 HPLC system equipped with a YL9110 quaternary pump, a YL9101 vacuum
degasser and a YL9160 PDA detector, linked to YL-Clarity software for data analysis (v3.0.4.444,
Young Lin, Hogye-dong, Anyang, Korea, 2009). The column was a Teknocroma C18 mediterranea
Sea 25 × 0.46 cm, the PDA wavelengths were set at 220–290 nm, the eluent flow was 1 mL/min,
and the gradient was 0 min: 100% water, 20 min: 100% acetonitrile, 30 min: 100% acetonitrile, and
35 min: 100% water. 1H NMR spectra were recorded on a Jeol ECZ-R 600, at 600 and 150 MHz,
respectively, using SiMe4 as the internal standard. The following abbreviations are used to designate
peak multiplicity: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet. ESI–MS spectra
were recorded on a Micromass Quattro API micro (Waters Corporation, Milford, MA, USA) mass
spectrometer. Data were processed using a MassLynx System (Waters).
2.2.3. PEGylated Linker Stearyl-PEG-Maleimide (ST-PEG-MBS) Synthesis
An in house engineered synthesis was developed for the ST-PEG-MBS. In the first step, 10 mg
stearic acid (140 mM), 1.25 mg NHS (43 mM) and 1 mg EDC (26 mM) were dissolved in 0.25 mL DMF
anhydrous and were kept reacting overnight at 45 ◦C. The reaction mixture was diluted with 1 mL
chloroform and washed with 4 mL 0.1 M HCl to eliminate water soluble compounds. The organic
phase was treated with MgSO4 and dried under nitrogen steam and checked through TLC (0.5%
triethylamine in chloroform): being in excess of stearic acid, it was a mixture of the reagent and of
activated stearic acid (36%). In a second step, 6.1 mg first step reaction product (corresponding to
2.2 mg activated stearic acid—12 mM), 2 mg MBS (12 mM), 12 mg diamino-PEG (12 mM) and 12 µL
triethylamine (237 mM) were dissolved in 0.5 mL chloroform and were kept reacting overnight at 45 ◦C.
The reaction mixture was dried under nitrogen steam, then the residue was dissolved in 400 µL ethanol,
and 1.6 mL 1 M HCl was added to precipitate un-reacted stearic acid from the first step reaction. The
obtained solution underwent size exclusion through a Sephadex G10 column to eliminate compounds
with Mw < 500. ST-PEG-MBS was purified from un-reacted diamino-PEG through Dowex 50WX8-200
resin. The purified solution was freeze dried. The obtained conjugate (6.4 mg) was checked through
TLC (acetic acid/chloroform/methanol 1/84/15) and characterized by 1H-NMR (300 MHz 1H was
recorded on a Bruker 300 Avance instrument (Bruker, Billerica, MA, USA) at 25 ◦C). The product was
characterized through HPLC. Analyses were performed with a YL9100 HPLC system equipped with a
YL9110 quaternary pump, a YL9101 vacuum degasser and a YL9160 PDA detector, linked to YL-Clarity
software for data analysis (Young Lin, Hogye-dong, Anyang, Korea), and, alternatively, with a LC10
HPLC UV system (Shimadzu, Tokyo, Japan) equipped with a ELSD detector, linked to a Class LC10
software for data analysis. The column was a Teknocroma C18 mediterranea Sea 25× 0.46 cm, the PDA
wavelengths were set at 220–290 nm, the eluent flow was 1 mL/min, and the gradient was 0 min: 100%
water, 20 min: 100% acetonitrile, 30 min: 100% acetonitrile, and 35 min: 100% water.
2.2.4. Protein Thiolation
Thiolated TRF (TRF-SH)
The thiolation of TRF was performed according to the literature with modifications [15].
A diluted solution of TCEP (5.7 µg/mL) in 0.1 M phosphate buffer at pH = 7.4 was prepared. Then,
2-iminothiolane was dissolved in this solution at various concentrations (ranging from 3.5 µg/mL
to 14.0 µg/mL). To dissolve 1 mg TRF, 1 mL of this solution was employed and was kept reacting
for 1 hour. Three different 2-iminothiolane/TRF molar ratios were employed: 2:1, 4:1, and 8:1.
The TRF-SH underwent purification through size exclusion (Biogel P-6, BioRad, Hercules, CA, USA)
and characterization through electrophoresis.
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Thiolated INS (INS-SH)
The INS thiolation procedure was modified from the literature [16]. The 2-iminothiolane was
dissolved in the above mentioned diluted TCEP solution at a concentration of 12.5 µg/mL, together
with EDTA at a concentration of 150 µg/mL. INS was dissolved in this solution at a concentration of
0.5 mg/mL and was kept reacting for 1 h. The molar ratio between the peptide and 2-iminothiolane
was 1:1. The INS-SH was purified through selective precipitation at pH = 5.0 and characterized
through electrophoresis.
2.2.5. SLN Preparation
According to the coacervation method described in a previous paper, 1% stearic acid SLNs were
prepared [17]. Briefly, sodium stearate was dispersed in an aqueous solution of the polymeric stabilizer
(PVA9000), and the mixture was then heated under stirring (300 rpm) up to a temperature of 50 ◦C to
obtain a clear solution. A 1 M lactic acid solution (coacervating solution) was then added dropwise.
The obtained suspension was then cooled in a water bath under stirring at 300 rpm until a temperature
of 15 ◦C was reached.
The 1% behenic acid SLNs were prepared as follows. Sodium behenate was dispersed in water
with PVA9000 and the mixture was then heated under stirring (300 rpm). A concentration of 1 M
sodium hydroxide was added to obtain a completely clear micellar solution. First, 5 M ammonium
chloride and then 1 M hydrochloric acid were added drop-wise to the mixture until complete behenic
acid precipitation [18]. The obtained suspension was then cooled under stirring at 300 rpm until a
temperature of 15 ◦C was reached.
ddMTX was dissolved in a small amount of hot ethanol and added to the micellar solution prior
to acidification.
2.2.6. SLN Functionalization
Maleimide linkers were dissolved in small amount of ethanol and added to the micellar solution
prior to acidification. Purified thiolated protein solution was added to the SLNs and kept stirring
overnight. Afterwards, the suspension was centrifuged at 26,000 rpm for 30 min (Allegra® 64R
centrifuge, Beckmann Coulter, Paolo Alto, CA, USA). The precipitate was re-suspended in 1% PVA9000
solution and protein grafting was assessed by electrophoresis. The obtained suspension was reacted
overnight with an excess of reduced glutathione in order to saturate unreacted maleimide groups
grafted onto the surfaces of SLNs, and, then, underwent size exclusion chromatography (Sepharose
CL-4B, Sigma Aldrich, Saint Louis, MO, USA) to completely eliminate unbound proteins. The obtained
sample was subject to electrophoresis, to estimate the amount of protein effectively bound to the SLNs.
2.2.7. SLN Coating with PVA120000
The SLNs obtained through the coacervation method were stabilized by PVA9000. A suitable
procedure was set up to obtain PVA120000 coating. Briefly, the ddMTX-loaded SLNs, plain or
functionalized with proteins, were centrifuged at 26,000 rpm for 30 min (Allegra® 64R centrifuge,
Beckmann Coulter, Paolo Alto, CA, USA). The precipitate was concentrated to 2.5% lipid through
re-suspension in a 25 mg/mL PVA120000 solution.
2.2.8. SLN Characterization
The particle size of the SLNs and polydispersity index were determined 1 h after preparation
using the dynamic light scattering (DLS) technique (90Plus, Brookhaven Instrument Corporation,
Holtsville, NY, USA). Size measurements were obtained at an angle of 90◦ at 25 ◦C. All data were
determined in triplicate.
The ddMTX content in the suspension was determined through fluorescence RP-HPLC after a
500-fold water dilution and derivatization.
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The amount of protein grafted onto the surfaces of the SLNs was determined through
electrophoresis and densitometry.
Preliminary drug release experiments and SLN stability studies were performed in cell culture
medium and plasma (Supplementary Materials, Figure S2, Table S1).
2.2.9. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS_PAGE)
To verify the effective functionalization of the SLNs, 10 µL TRF-SH and INS-SH SLN, mixed
with 5 µL Laemly Buffer (60 mmol/L Tris-Cl, pH 6.8; 2% w/v SDS; 10% v/v glycerol, 5% v/v
β-mercaptoethanol; 0.01% w/v bromophenol blue) were separated by SDS-PAGE. 10 µg purified
TRF or INS, diluted in 10 µL Laemly Buffer, were loaded as the internal standard. The electrophoresis
was performed without heating samples, to avoid TRF or INS denaturation and/or detachment from
the SLNs, loading samples onto a 12% (for TRF-SLNs) or 15% SDS-polyacrylamide (for TRF-SLNs)
running gel (Bio-Rad). The running conditions were 100 V for 1 h. After the electrophoretic separation,
to detect the free TFR or INS, or the protein grafted onto SLNs, the gels were stained with 10 mL
Coomassie BrilliantBlue solution, that can detect 100–500 ng of protein per spot [19] (0.2% w/v
Coomassie Blue, 7.5% v/v acetic acid and 50% v/v ethanol), for 1 h at room temperature, followed by
overnight de-staining with deionized water. Densitometry was performed with ImageJ 1.50i Software
(National Institute of Health, Bethesda, MD, USA, 2016).
2.2.10. Permeability through hCMEC/D3 Cell Monolayer
hCMEC/D3 cells, seeded as reported above in Transwell devices, were incubated at day 7 with
either the free drug (MTX) or the SLN-entrapped drug (ddMTX-loaded SLNs), in the experimental
conditions described in the Results section. The medium in the lower chamber was then collected and
the amount of the drug was measured through fluorescence RP-HPLC.
2.2.11. In Vivo Biodistribution
The ddMTX-loaded SLNs, and disodium MTX (1 mg/kg) solution in normal saline, were
administered through a catheter surgically positioned in the jugular vein of male Wistar healthy
rats (weight, 250 g) [20]. At scheduled times, the rats were sacrificed by CO2-induced euthanasia;
plasma was withdrawn, and the organs (liver, spleen, kidneys, lungs, heart and brain) were removed
surgically. Blood samples were collected in heparinized tubes and centrifuged to isolate plasma. Urine
was withdrawn through a syringe from the bladder. The brain underwent capillary depletion to isolate
brain capillaries from parenchyma. Briefly, freshly removed brains were manually homogenized with a
potter in 3.5 mL Phosphate Buffered Saline (PBS) buffer; then 1 mL of the homogenate was diluted with
1.16 mL dextran 60,000–90,000 and underwent gradient centrifugation at 4000× g for 10 min at 25 ◦C
in a test tube (Allegra® 64R centrifuge, Beckmann Coulter, Paolo Alto, CA, USA). The capillaries were
isolated from the bottom of the tube [21]. Other organs were homogenized with UltraTurrax®(IKA,
Staufen, Germany) for 5 min in water at a tissue concentration of 125 mg/mL; tissue homogenates and
plasma underwent the derivatization reaction prior to fluorometric HPLC detection described below.
Each experiment was performed with four rats for each experimental condition (sample size
calculated with G*Power 3.1.9.2, Universitat Kiel, Kiel, Germany, 1992).
2.2.12. Enzymatic Synthesis of 7-Hydroxymethotrexate (7OH-MTX)
Isolation of Aldehyde Oxidase from Rabbit Liver
The rabbits were sacrificed in a slaughterhouse for food purposes. The liver was isolated and kept
in an ice bath for 10 min prior to manipulation in the laboratory. Aldehyde oxidase was isolated from
liver according to a literature method with slight modifications [22,23]. An amount of 10 g of tissue was
homogenized with UltraTurrax (Ika, Staufen, Germany) in 1.15% KCl in an ice bath. The homogenate
was centrifuged at 10,000× g for 30 min at 4 ◦C (J2-21 centrifuge, Beckmann Coulter, Paolo Alto,
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CA, USA). The supernatant was separated and heated to 55 ◦C for 10 min: after rapid cooling, a
precipitate was obtained and it was isolated through centrifugation at 15,000× g for 45 min at 4 ◦C
(J2-21 centrifuge, Beckmann Coulter, Paolo Alto, CA, USA). The supernatant was isolated, ammonium
sulphate was added in order to give 50% saturation, and the mixture was gently shaken at 4 ◦C for
20 min and successively centrifuged at 6000× g for 30 min at 4 ◦C (J2-21 centrifuge, Beckmann Coulter,
Paolo Alto, CA, USA). The precipitate was suspended in 5 mL 0.05 M buffer phosphate pH = 7.8 with
0.1 mM EDTA. The same buffer was employed for elution on a Sephadex G75 column. The fractions
showing significant absorbance at λ = 280 nm were put together and successively fractioned in aliquots,
and kept at −80 ◦C until usage. Protein determination in the enzyme solution was performed using
the Folin–Ciocolteu method, employing bovine albumin as the standard.
The isolated enzyme corresponds to a mixture of aldehyde oxidase and xanthine oxidase: the
first is the major component involved in MTX oxidation, but, given that the second could contribute,
no further purification was performed.
The activity of the enzyme was determined spectrophotometrically (Cary 50 Bio, Varian,
Paolo Alto, CA, USA) at 37 ◦C in 67 mM phosphate buffer at pH = 7.0. The oxidation rate of
3-methylisoquinoline (0.250 mM) was monitored at 420 nm by following potassium ferricynide
reduction [24].
7OH-MTX Synthesis from MTX
Synthesis was performed according to the literature with modifications [25]. Briefly, 5 mg MTX
were dissolved in 33 mL 0.133 M Sorensen buffer brought to pH = 7.8 with 5 M sodium hydroxide.
An amount of 10 mL enzyme solution (corresponding to 112 mg enzyme) was slowly unfrozen in an
ice bath and then added to the MTX solution. The mixture was kept at 37 ◦C for 2 h. Afterwards the
pH was brought to 8.4 with 0.5 M sodium hydroxide and kept at 40 ◦C overnight. The mixture was
centrifuged at 5000 rpm (Rotofix 32A centrifuge, Hettich, Tuttlingen, Germany) and the supernatant
was isolated, heated until 70 ◦C and centrifuged. Complete deproteinization was obtained with
Amicon Centriflo (Millipore, Burlington, MS, USA) equipped with 50,000 Da dialysis membrane.
The dialyzed solution was brought to pH = 4.0 with acetic acid and kept at 4 ◦C overnight in order to
obtain the complete precipitation of 7OH-MTX. The obtained suspension was centrifuged at 25,000 rpm
(Allegra® 64R centrifuge, Beckmann Coulter, Paolo Alto, CA, USA), the supernatant was discarded
and the precipitate was dried under vacuum. Nearly 2 mg 7OH-MTX was obtained. The reaction
product was assessed through PDA–HPLC described below and the eluted fractions were collected
and analyzed with mass spectroscopy (Micromass Quattro microTM API, Waters Corporation, Milford,
MA, USA).
2.2.13. MTX, 7OH-MTX and ddMTX HPLC Analysis
Analyses were performed with a YL9100 HPLC system equipped with a YL9110 quaternary pump,
a YL9101 vacuum degasser and a YL9160 PDA detector and/or a Shimadzu RF-10A fluorescence
detector (Shimadzu, Tokyo, Japan), linked to YL-Clarity software for data analysis (Young Lin,
Hogye-dong, Anyang, Korea).
(Photo Diode Array Detector) PDA HPLC of MTX and 7OH-MTX
HPLC analysis was performed with Mediterranea Sea RP 2.5 µm 250 × 0.46 cm
column (Tecnokroma, Barcelona, Spain). The mobile phase was ammonium acetate 0.1
M/methanol/acetonitrile (87/5/8), used at 1 mL/min flow. The PDA detector was set at λ = 305 nm.
The retention times were 17.0 and 20.0 min for MTX and 7OH-MTX, respectively.
Derivatization and Fluorescence HPLC of MTX and ddMTX
The RP-HPLC method was developed for the determination of both MTX and ddMTX in biological
samples, based on a method in the literature [26]. Briefly, 0.25 mL of samples was added to 0.1 mL 10%
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SDS aqueous solution, in order to promote ddMTX dissolution. Then, they were deproteinized with
0.08 mL of 10% trichloroacetic acid (TCA) and centrifuged. An amount of 0.2 mL of the supernatant
was added to 0.05 mL 5 M pH 5.0 acetate buffer. MTX or ddMTX were then oxidized to fluorescent
pterydin carboxylic acid with 0.05 mL 5% KMnO4. HPLC analysis was performed with Mediterranea
Sea RP 2.5 µm 150 × 4.6 mm column (Tecnokroma, Barcelona, Spain). Here, 0.05 M pH 6.7 TRIS buffer
(adjusted with phosphoric acid) was used as a mobile phase at 1 mL/min flow. After peak elution,
the gradient was performed with 30% acetonitrile in order to clean the column from the reaction
sub-products. Folic acid was employed as the internal standard. The retention time was 12 min for
MTX. R2 0.99, Limit of Detection (LOD) 0.01 µM, Limit of quantification (LOQ) 0.03 µM, Bias 3%,
Coefficient of Variation (CV) 5.3%, Recovery 87%.
Ultra-High Performance Liquid Chromatography (UPLC–MS) Analysis of MTX and its Metabolites
The derivatized samples also underwent UPLC–MS analysis according to the following conditions.
UPLC–MS analysis was performed with an Acquity UPLC (Waters Corporation, Milford MA, USA),
equipped with Binary Solvent Manager (BSM), Sample Manager (SM), Column Manager (CM) and
PDA detectors. The analytical column was a Zorbax Eclipse XDB-C18 150 × 4.6 mm. The mobile phase
consisted of methanol and ammonium acetate buffer pH = 6.0 (30/70). UPLC retention time (Rt) was
obtained at flow of 0.4 mL/min, and the column effluent was monitored using Micromass Quattro
microTM API Esci multi-mode ionization enabled as detector. The MS conditions were: purging gas
(nitrogen) heated at 350 ◦C, at a flow rate of 800 L/h; nebulizer gas (nitrogen) at 80 L/h; capillary
voltage in the negative mode at 3000 V; fragmentor voltage at 20 V.
2.2.14. Statistical Analysis
Results were reported as mean± standard deviation, and statistical analysis was performed using
a two-tailed Student’s t-test (Prism Graphpad 7.0, Graphpad Software, San Diego, CA, USA, 2016).
3. Results
The ddMTX-loaded stearic acid and behenic acid SLNs were formulated according to the fatty acid
coacervation technique [17]. The ddMTX characterization is shown in the Supplementary Materials.
The ddMTX-loaded SLN composition and characterization are shown in Table 1. The behenic acid
SLNs were prepared according to an optimized composition, in order to obtain a more homogeneous
nanosuspension with a reduced polydispersity and particle size [18]. PVA120000 was also employed
as a suspending/coating agent, as an alternative to PVA9000, in order to improve biodistribution in
the plasma compartment: in this case, PVA9000 was removed by centrifugation and the SLNs were
re-suspended in a PVA 120000 solution. Re-suspension in PVA120000 resulted in a slight increase in
particle size, probably due to the viscosity of the polymer.
Preliminary biodistribution experiments were performed by sacrificing the animals 30 min after
the IV administration of ddMTX-loaded SLNs, aiming to compare drug accumulation in the tissues
between SLNs with different lipid matrixes/stabilizing polymers and free MTX. A higher persistence
in tissues was noted when the drug was loaded in behenic acid SLNs compared to free MTX, except for
the kidneys. However, a higher plasmatic concentration is necessary in order to optimize the contact
with BBB cells and favor its overcoming. The employment of PVA120000 as a suspending agent led to
an increased drug concentration in plasma (Figure 1). Thus, the ddMTX-loaded behenic acid SLNs
stabilized with PVA120000 were employed for the following studies with functionalized SLNs.
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Table 1. Composition and characterization of the unfunctionalized ddMTX-loaded SLNs.
Lipid Matrix Stearic Acid Behenic Acid
Stabilizer PVA9000 PVA9000 PVA120000
Composition
Sodium stearate (mg) 25 - -
Sodium behenate (mg) - 25 25
PVA9000 (mg) 25 50 50 1
PVA120000 (mg) - - 25
1 M Lactic acid (µL) 125 - -
1 M sodium hydroxide (µL) - 30 30
5 M ammonium chloride (µL) - 65 65
1 M hydrochloric acid (µL) - 100 100
ddMTX (mg) 2.0 2.0 2.0
Distilled water (mL) 2.5 2.5 1 2
Characterization
Mean size (nm) 353 ± 35 351 ± 45 435 ± 33
Polydispersity 0.240 0.155 0.250
ddMTX (mg/mL) 0.71 0.78 0.81
1 partially removed after centrifugation; 2 after centrifugation and resuspension in PVA120000 solution
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Using the 8:1 and 4:1 2-iminothiolane/TRF molar ratios, TRF-SH was present in its dimerized form 
(Figure 2A,B blue boxes; 150 kDa band): this indicates protein aggregation due to disulfide bond 
formation. Disulfide bonds reduce the efficacy of following protein grafting onto SLNs through 
reaction with maleimide linkers. Thus, a 2:1 molar ratio was employed, allowing plain TRF-SH 
retention (Figure 2C,E lanes 2 red boxes; 75 kDa band). Since the dimerization of INS-SH was less 
detectable by electrophoresis (Figure 2D,F), a 1:1 2-iminothiolane/INS molar ratio was used, in order 
to minimize the possibility of disulfide bond formation. 
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Functionalization with proteins was achieved by grafting a maleimide moiety on the
nanoparticle’s surface through a properly synthesized linker, and exploiting its reactivity towards
the thiolated proteins. The derivatization was confirmed by SDS-PAGE followed by Blue Coomassie
staining. The ST- BS and ST-PEG- BS characterizations are shown in the Supplementary aterials
(Figure S1).
The preli inary studies were perfor ed in order to opti ize the thiolation of proteins.
Electrophoresis was carried out to investigate the effect of 2-i inothiolane/TRF olar ratio on the
protein aggregation caused by disulfide bond for ation (Figure 2A lane 3, Figure 2B,C,E, lanes 2).
Using the 8:1 and 4:1 2-i inothiolane/TRF molar ratios, TRF-SH was present in its di erized for
(Figure 2A,B blue boxes; 150 kDa band): this indicates protein aggregation due to disulfide bond
for ation. Disulfide bonds reduce the efficacy of following protein grafting onto SLNs through
reaction with alei ide linkers. Thus, a 2:1 olar ratio was e ployed, allowing plain TRF-SH
retention (Figure 2C,E lanes 2 red boxes; 75 kDa band). Since the di erization of INS-SH was less
detectable by electrophoresis (Figure 2D,F), a 1:1 2-i inothiolane/INS olar ratio was used, in order
to ini ize the possibility of disulfide bond for ation.
Pharmaceutics 2019, 11, 65 10 of 18Phar aceutics 2018, 10, x FOR PEER REVIEW 10 of 18 
 
 
(A) (B) 
 
(C) (D) 
 
(E) (F) 
Figure 2. Electrophoresis. Red boxes: free proteins; blue boxes: dimerized proteins; yellow boxes: 
proteins grafted onto SLNs. (A) ST-MBS; 8:1 2-iminothiolane/TRF molar ratio; (B) ST-MBS; 4:1 
2-iminothiolane/TRF molar ratio; (C) ST-MBS; 2:1 2-iminothiolane/TRF molar ratio; (D) ST-MBS; 1:1 
2-iminothiolane/INS molar ratio; (E) ST-PEG-MBS; 2:1 2-iminothiolane/TRF molar ratio; (F) 
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ST-PEG-MBS (mg) - - 1.0 1.0 
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Distilled water (mL) 1 2 1 2 1 2 1 2 
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The co position and characterization of ddMTX-loaded behenic acid SLNs, functionalized with
proteins, is shown in Table 2.
Table 2. Composition and characterization of the functionalized ddMTX-loaded behenic acid SLNs.
Linker ST-MBS ST-PEG-MBS
Protein linked TRF INS TRF INS
Co ition
Sodium behenate (mg) 25 25 25 25
PVA9000 (mg) 50 1 50 1 50 1 50 1
PVA120000 (mg) 25 25 25 25
1 M sodium hydroxide (µL) 30 30 30 30
5 M ammonium chloride (µL) 65 65 65 65
1 M hydrochloric acid (µL) 100 100 100 100
ddMTX (mg) 2.0 2.0 2.0 2.0
ST-MBS (mg) 0.2 0.2 - -
ST-PEG-MBS (mg) - - 1.0 1.0
TRF-SH (mg) 3.6 - 1.0 -
INS-SH (mg) - 3.6 - 1.0
Distilled water (mL) 1 2 1 2 1 2 1 2
Characterization
Mean size (nm) 437 ± 55 429 ± 8 500 ± 45 445 ± 41
Polydispersity 0.122 0.222 0.209 0.103
ddMTX (mg/mL) 0.95 0.36 0.51 0.41
Protein linked (µg/mg lipid) 27.8 18 3 2.2
1 partially removed after centrifugation, 2 after concentration through centrifugation and resuspension
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In electrophoresis, proteins grafting onto the surfaces of SLNs caused protein retention at the top
of the running gel [9], because of the larger size of the nanoparticles compared to proteins (Figure 2A
lane 4, Figure 2B–F lanes 3 yellow boxes). Blank SLNs were not detected in electrophoresis, as expected
(Figure 2A lane 2). Both ST-MBS and ST-PEG-MBS were allowed to graft proteins onto the surfaces of
SLNs, even if a higher amount was grafted with ST-MBS. Moreover, after size exclusion, the proteins
remained grafted onto the surfaces of SLNs almost completely when ST-MBS was used (Figure 2C,D
lanes 4 yellow boxes), while with ST-PEG-MBS a certain protein leakage was noted (Figure 2E,F lanes
4 yellow boxes), probably due to the major hydrophilicity of ST-PEG-MBS. Insulin grafting was more
labile and a small amount of free protein was also recovered in samples purified by size exclusion
(Figure 2D,F lanes 4 red boxes). Since a significantly lower amount of protein was grafted onto SLNs
with ST-PEG-MBS compared to ST-MBS, in the definitive preparation procedure a lower amount of
thiolated protein was employed for reaction with the first one, in order to avoid waste of reagents
(Table 2).
In vitro permeation studies on cellular models of BBB were performed in order to investigate
the ability of SLNs to target BBB endothelial cells (Figure 3). Unfunctionalized SLNs showed a
significantly increased delivery across the hCMEC/D3 cells monolayer, compared to free MTX. SLNs
functionalized through the ST-MBS linker were delivered more than the free MTX at all time points.
SLNs functionalized through the ST-PEG-MBS linker showed a lower delivery at a short incubation
time (1 h); after 24 h incubation, however, the delivery was higher than the free drug. Despite being an
unexpected result, the lower permeation of functionalized SLNs compared to unfunctionalized SLNs
at 24 h might be explained through the saturation of a receptor-mediated endocytosis mechanism.
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functionalized with ST-PEG-MBS, while almost absent when ST-MBS was employed (Figure 4B).  
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In vivo bio istrib tion experi ents ere perfor e ith f nctionalize -loa e S s
in or er to f rther investigate the role of protein functionalization on brain acc lation. In this
case, ani al sacrifice as one 3 h after I a inistration in or er to allo the prolonge contact of
nano articles ith cells, th s o ti izing brain acc lation. oreover, the ca illary e letion
etho as se to isolate brain en othelial cells. btained ata ere co are to free
(Figure 4). SLN functionalization with proteins increased drug accumulation in lungs, liver and spleen
(Reticulo Endothelial System—RES organs), regardless of the linker employed. However, accumulation
in brain parenchyma was sig ificantly lower compared to non-target organs; a significant increase
of brain accumulation was oted for SLNs functionalized with ST-PEG-MBS. Accumulation in brain
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capillaries was promising for unfunctionalized SLNs and SLNs functionalized with ST-PEG-MBS,
while almost absent when ST-MBS was employed (Figure 4B).
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i ll , fter the administration of d MTX-loaded SLNs, the presence of MTX and 7OH-MTX was
qualitatively investigated, because they can contribute to the pharmacological activity. Preliminary
evidence was obtain d from UPLC–MS: analyses were performed on urine of treated animals (shown
i the Supplementary Materials), that is the main site of accumulation of drug etabolites. MTX
and 7OH-MTX were identified as ddMTX metabolites (see Supplementary Materials), confirming
the prodrug hydrolysis and the parent drug metabolism [27,28]. Among the metabolites f MTX,
7OH-MTX is the most known active one [27,28]. Thus, a suit ble enzyme-assisted procedure [25] was
mployed to synthesize the metabolite starting directly from MTX: this method is solvent free and
allows avoiding the multi-step process required by chemical synthesis [29]. The results are shown
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in the Supplementary Materials. The synthesized drug allowed to confirm the identification of the
metabolite in UPLC–MS.
4. Discussion
The SLNs obtained using the fatty-acid coacervation method were loaded with ddMTX, an
ester prodrug of MTX that is active towards GB in vitro [8]. A range of factors that influence brain
biodistribution in vivo were considered.
Two lipid matrixes (stearic acid and behenic acid) were compared. An optimized formulation
technique for behenic acid SLNs was employed [18] in order to improve the homogeneity of the
nanoparticle suspensions.
Preliminary biodistribution experiments, performed via animal sacrifice 30 min after
administration, showed that ddMTX-loaded behenic acid SLNs have higher drug persistence in
tissues than free MTX (Figure 1). Nevertheless, with ddMTX-loaded behenic acid SLNs, the drug level
in plasma was low. Reduced particle size is an important parameter that contributes to prolonging
nanoparticle circulation in the bloodstream. In fact, nanoparticles with a diameter greater than 200 nm
activate the complement system and are quickly removed from the bloodstream, accumulating in
the liver and spleen more rapidly compared to smaller ones [30]. There is still debate as to whether
the rapid accumulation is due to simple filtration or increased binding opportunities between the
mononuclear cells and the nanoparticles [31]. However, despite being solvent free, easy to scale-up
and versatile [17], the coacervation technique struggles to provide SLNs with a mean diameter below
200 nm. On the other hand, surface lipophilicity increases the nanoparticle removal rate from the
bloodstream, thus they are frequently coated with hydrophilic polymers, such as polyethylene glycol
(PEG) to avoid the RES system and increase blood circulation half-life, despite the fact that coating with
PEG reduces the surface charge and negatively affects the cellular uptake [32]. Therefore, we focused
on improving the hydrophilic shell surrounding the SLNs, which should hamper opsonization. Apart
from PEG, other polymers forming a hydrophilic shell around the particles can be employed, such
as PVA, showing an improved efficacy by increasing molecular weight [33]. The SLNs produced by
coacervation were coated with PVA9000, a hydrophilic polymer, whose reduced molecular weight,
however, favors its rapid elimination by the kidneys [34]. Re-suspending the SLNs in PVA120000 led
to higher drug levels in the plasma, despite a slight increase in the mean diameter of the nanoparticles
(Figure 1). Its high molecular weight means that PVA120000 is eliminated by the kidneys more slowly
than PVA9000. This fact might stabilize the nanoparticles in the bloodstream and it is in agreement
with the literature data [33]. Being coated and sterically stabilized by the non-ionic PVA, the SLNs
by coacervation did not show any Zeta potential (data not shown). Nevertheless, their mean size
increased when resuspended in PVA120000, probably because of its higher molecular weight. Thus,
even if the particle size increased, the concentration in the bloodstream increased, probably because of
the effect of PVA120000 on opsonization.
The ddMTX-loaded behenic acid SLNs that were stabilized with PVA120000 were functionalized
with two proteins (TRF or INS), whose receptors are abundantly expressed in BBB endothelial
cells. The proteins were thiolated and grafted, through either a lipophilic (ST-MBS) or a PEGylated
(ST-PEG-MBS) linker, both of which expose a maleimide moiety on the surfaces of SLNs. ST-MBS
was synthesized according to a method in the literature [14]. ST-PEG-MBS was synthesized and
characterized in house (Supplementary Materials). According to 1H NMR, the maleimide protons
were detected as a multiplet at 6.5 ppm and the stearic moiety could be easily evidenced at high field
(1.2 ppm multiplet for the alkylic chain and 0.9 ppm for the methyl moiety). Both maleimide and
stearic moiety were linked to diamino-PEG in a 1:1 molar ratio. The thiolation of proteins is frequently
associated with aggregation due to the formation of disulfide bonds: to this aim, EDTA is frequently
used to scavenge metals that favor thiol oxidation. EDTA, however, cannot be employed with TRF
because it would sequestrate iron, leading to so-called holo-TRF, which possesses a low affinity for the
TRF receptor. A mild reducing agent, TCEP, was therefore used to inhibit thiol oxidation. This decision
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was made on the basis of the literature data [15]. The 2-iminothiolane/protein ratio was also optimized
in order to avoid protein aggregation (Figure 2). The functionalization and purification of the SLNs
were followed step-by-step through electrophoresis. Size exclusion was employed to eliminate free
proteins. The unreacted maleimide moiety present on the surfaces of SLNs was saturated with an
excess of reduced glutathione in order to avoid the targeting of the heart and muscle (data not shown)
that would occur because of a reaction between maleimide and the free thiol group of myosin [35].
The first evaluation of functionalized SLNs was performed in vitro (Figure 3). Indeed, ddMTX
has a poor permeability across BBB [8] due to the presence of ATP binding cassette transporters on
the luminal side such as P-glycoprotein (Pgp), Multidrug resistance Related Proteins (MRP) 1, 2 and 4
and the Breast Cancer Resistance Protein (BCRP) that extrude the MTX derivatives from endothelial
cells back to the blood stream [36]. By contrast, we recently demonstrated that the loading of ddMTX
onto SLNs significantly increased drug delivery across the BBB [8]. If not functionalized, SLNs—as
most nanoparticles and/or liposomes—are subjected to macropynocytosis that allows an efficient
route of internalization of SLNs. The internalization is followed by the fusion of macropynocytic
vesicles with endosomal/lysosomal compartments and the release of SLN cargo within the cytosol [37].
After this step, the released ddMTX may be effluxed towards brain parenchyma by MRP3, an ABC
transporter located on the basolateral membrane of BBB that transports MTX-derivatives [36]. The sum
of the increased endocytosis, subtraction of ddMTX from the backward efflux through Pgp, MRP1,
MRP2, MRP4 and BCRP, and the increased basolateral efflux of ddMTX through MRP3 following
the endocytosis of ddMTX-SLNs may justify the increased delivery of the compound when loaded
onto SLNs compared to delivery obtained as free drug. Paradoxically, protein grafting onto SLNs
makes SLN permeation slower. This can be due to the fact that the functionalized SLNs exploit a
receptor-mediated system, which undergoes saturation. Moreover, one of the mechanisms of SLN
internalization can be the endocytosis mediated by clathrin-coated vesicles. This mechanism has been
demonstrated for instance for the transcellular uptake of apoE-conjugated SLNs in BBB cells, where
it represents the predominant transcellular pathway of internalization [38]. We cannot exclude that
the lower delivery of conjugated SLNs versus unconjugated SLNs was also due to the saturation of
clathrin-dependent endocytosis in our system. Whatever the mechanism is, this effect is more evident
in SLNs that are functionalized with ST-PEG-MBS, but also occurs when ST-MBS is employed. It is
important to note, however, that all the SLN formulations provided higher drug delivery across the
BBB after 24 h than the free drug.
Frequently, the biodistribution of nanoparticles showed a strong correlation to nanoparticle
size with the smaller sized particles that are able to pass the BBB [32]. However, the capability of
polybutylcyanoacrylate nanoparticles larger than 200 nm to successfully overcome BBB is documented
by a recent publication [39]. Interestingly, the nanoparticles’ surface chemical properties, and not
particle size, resulted to be the parameter with the most significant influence on BBB passage. Different
factors at the target site (the BBB) and in the bloodstream should be taken in account. In vitro
experiments with BBB cell models mimic the target site and demonstrate that all the SLN formulations
under study, functionalized or not, provided drug delivery across the BBB according to endocytosis
mechanisms, regardless of their size. The in vivo fate of nanoparticles is more complex and depends
on the interaction with bloodstream components. Having a high concentration of nanoparticles in
the blood stream means that the nanoparticles have more contact with the BBB endothelial cells,
favoring the endocytosis process [40]. This is a relevant factor that, in the case of SLNs stabilized
with PVA120000, can influence the ability to overcome the BBB. However, we are aware that in vitro
experiments on cellular BBB models are not fully comparable with in vivo experiments. In fact, drug
distribution and elimination phases are not present in the Transwell system and the formulations
are kept in contact with the endothelial cell monolayer for a longer time than in in vivo conditions,
enhancing non-specific endocytosis phenomena. In vivo, instead, rapid clearance of SLNs from the
blood stream avoids receptor saturation, emphasizing the role of specific SLN functionalization.
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We then moved to the more physiological in vivo setting. Preliminary experiments with
unfunctionalized SLNs stabilized with PVA120000 showed promising drug concentrations in plasma
30 min after administration (Figure 1). Consequently, we hypothesized that a longer time frame
after administration would have prolonged the contact between the SLNs and the BBB, thus
optimizing endocytosis by the endothelial cells. Thus, biodistribution experiments on functionalized
ddMTX-loaded SLNs were performed by sacrificing the animals 3 h after administration of the
formulations under study. The drug concentration in the brain was lower than that in non-target
tissues. However, interesting differences between ST-MBS and ST-PEG-MBS grafted SLNs were
noted (Figure 4). Although a higher protein amount was grafted with ST-MBS (Tables 1 and 2),
brain biodistribution was improved only when ST-PEG-MBS was used. Furthermore, capillary
depletion showed no endothelial-cell internalization for ST-MBS-grafted SLNs and good uptake
for ST-PEG-MBS-grafted SLNs. The presence of a PEG spacer between the nanoparticles and the
targeting protein is considered important for the interaction with the receptor [41]. Moreover, TRF
and INS receptors are expressed not only in the BBB endothelial cells, but also in various tissues
(including macrophages and RES organs), while the protein grafting of a nanoparticulate system is
thought to increase its immunogenicity. Unpredictable variations in in vivo biodistribution should
thus be expected. It has been reported that the protein density on the nanoparticle’s surface and the
strength of the interaction between the ligand and the receptor in the target tissue play a key role for
protein-targeted nanoparticles [42]; selective targeting to endothelial cells is obtained when a lower
amount of protein is grafted onto the nanoparticles, while a higher amount generally drives towards
macrophages and RES [43]. In fact, ST-PEG-MBS grafting should target SLNs to the BBB, most likely
because of the improved interactions with the receptor and the reduced amount of protein grafted onto
the surfaces of SLNs. ST-MBS grafting, instead, probably addresses mainly towards non-target organs.
This difference was not observed to be so strong in in vitro experiments, where only the receptors that
are expressed on endothelial cells are involved, and interactions with non-target organs, which occur
in vivo, are excluded.
The ddMTX prodrug was metabolized in vivo: MTX and 7OH-MTX were identified in animals
administered with ddMTX-loaded SLNs. Indeed, the metabolism plays a key role in the clearance
of the drug. With the liver being the main organ of accumulation, it can be the subject of off-target
toxic effects. Thus, future studies will also need to evaluate the biodistribution of the drug and its
metabolites at longer time points after administration (i.e., 24 h), in order to investigate the safety of
the formulation.
5. Conclusions
In this experimental work, ddMTX-loaded SLNs were formulated, surface engineered and
functionalized with TRF and INS, and then tested in vitro and in vivo to overcome the BBB.
Functionalization was achieved by grafting onto the nanoparticle’s surface a maleimide linker and
exploiting its reactivity towards thiolated proteins. The reaction conditions were optimized in order
to avoid protein aggregation due to disulfide bond formation. The employment of ST-PEG-MBS
transported SLNs towards the BBB in vivo, while ST-MBS transported SLNs towards non-target
organs, probably because of the different amounts of protein bound onto the surfaces of SLNs.
The in vitro data on cells might suggest that such formulations overcome the BBB according to
receptor-mediated endocytosis that can undergo saturation. On the basis of the promising results in
terms of biodistribution, we are going to perform further studies on in vivo glioma models in order to
evaluate the potential application of functionalized SLNs to GB therapy.
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